Brincidofovir (BioDeep_00000837591)
代谢物信息卡片
Brincidofovir
化学式: C27H52N3O7P (561.3542692)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O
InChI: InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10547
- PubChem: 483477
- DrugBank: DB12151
- ChEMBL: CHEMBL203321
- CAS: 444805-28-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Nozomu Hanaoka, Masatoshi Hazama, Koji Fukushima, Tsuguto Fujimoto. Sensitivity of Human Mastadenovirus, the Causal Agent of Pharyngoconjunctival Fever, Epidemic Keratoconjunctivitis, and Hemorrhagic Cystitis in Immunocompromised Individuals, to Brincidofovir.
Microbiology spectrum.
2022 02; 10(1):e0156921. doi:
10.1128/spectrum.01569-21. [PMID: 35171015] - Scott Parker, June D'Angelo, R Mark Buller, Donald F Smee, Johan Lantto, Henriette Nielsen, Allan Jensen, Mark Prichard, Sarah L George. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Antiviral research.
2021 11; 195(?):105179. doi:
10.1016/j.antiviral.2021.105179. [PMID: 34530009] - Shuk Ying Chan, Susan E Prockop, Farid Boulad, Genovefa A Papanicolaou, Yeon Joo Lee. Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection.
Infection & chemotherapy.
2021 Sep; 53(3):572-577. doi:
10.3947/ic.2020.0204. [PMID: 32869551] - Bryan B Guzman, Amanda P Schauer, John A Dunn, Mackenzie L Cottrell, Craig Sykes. A quantitative LC-MS/MS method for the determination of tissue brincidofovir and cidofovir diphosphate in a MuPyV-infected mouse model.
Biomedical chromatography : BMC.
2021 May; 35(5):e5061. doi:
10.1002/bmc.5061. [PMID: 33398885] - Christina L Hutson, Ashley V Kondas, Mathew R Mauldin, Jeffrey B Doty, Irma M Grossi, Clint N Morgan, Sharon Dietz Ostergaard, Christine M Hughes, Yoshinori Nakazawa, Chantal Kling, Brock E Martin, James A Ellison, Darin S Carroll, Nadia F Gallardo-Romero, Victoria A Olson. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
mSphere.
2021 02; 6(1):. doi:
10.1128/msphere.00927-20. [PMID: 33536322] - Jackson Londeree, Pamela D Winterberg, Rouba Garro, Roshan P George, Stella Shin, Rochelle Liverman, Anastacia Serluco, Rene Romero, Inci Yildirim. Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series.
Pediatric transplantation.
2020 11; 24(7):e13769. doi:
10.1111/petr.13769. [PMID: 32558134] - Joshua A Hill, W Garrett Nichols, Francisco M Marty, Genovefa A Papanicolaou, Thomas M Brundage, Randall Lanier, Danielle M Zerr, Michael J Boeckh. Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT.
Blood.
2020 04; 135(17):1447-1451. doi:
10.1182/blood.2019004315. [PMID: 32076716] - Julio J Alvarez-Cardona, Laura K Whited, Roy F Chemaly. Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections.
Future microbiology.
2020 04; 15(?):389-400. doi:
10.2217/fmb-2019-0288. [PMID: 32166967] - Mostafa A Hussien, Ahmed E M Abdelaziz. Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease.
Network modeling and analysis in health informatics and bioinformatics.
2020; 9(1):56. doi:
10.1007/s13721-020-00263-6. [PMID: 32834922] - Jagdish P Meena, Robert S Phillips, Sally Kinsey. Brincidofovir as a Salvage Therapy in Controlling Adenoviremia in Pediatric Recipients of Hematopoietic Stem Cell Transplant.
Journal of pediatric hematology/oncology.
2019 10; 41(7):e467-e472. doi:
10.1097/mph.0000000000001480. [PMID: 30969265] - Gloria Bua, Ilaria Conti, Elisabetta Manaresi, Phiroze Sethna, Scott Foster, Francesca Bonvicini, Giorgio Gallinella. Antiviral activity of brincidofovir on parvovirus B19.
Antiviral research.
2019 02; 162(?):22-29. doi:
10.1016/j.antiviral.2018.12.003. [PMID: 30529090] - Yeon Joo Lee, Dionysios Neofytos, Seong Jin Kim, Leslie Cheteyan, Yao-Ting Huang, Esperanza B Papadopoulos, Ann A Jakubowski, Genovefa A Papanicolaou. Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society.
2018 Dec; 20(6):e12977. doi:
10.1111/tid.12977. [PMID: 30120866] - Santiago M C Lopez, Marian G Michaels, Michael Green. Adenovirus infection in pediatric transplant recipients: are effective antiviral agents coming our way?.
Current opinion in organ transplantation.
2018 08; 23(4):395-399. doi:
10.1097/mot.0000000000000542. [PMID: 29846196] - Nimisha Sulejmani, Shunji Nagai, Mohamed Safwan, Michael D Rizzari, Mohammad Raoufi, Marwan S Abouljoud, Mayur Ramesh. Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients.
Pharmacotherapy.
2018 04; 38(4):470-475. doi:
10.1002/phar.2094. [PMID: 29457839] - Prashant Hiwarkar, Persis Amrolia, Ponni Sivaprakasam, Su Han Lum, Hemalatha Doss, Ciara O'Rafferty, Toni Petterson, Katharine Patrick, Juliana Silva, Mary Slatter, Sarah Lawson, Kanchan Rao, Colin Steward, Adam Gassas, Paul Veys, Robert Wynn. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant.
Blood.
2017 04; 129(14):2033-2037. doi:
10.1182/blood-2016-11-749721. [PMID: 28153824] - Michael S Grimley, Roy F Chemaly, Janet A Englund, Joanne Kurtzberg, Gregory Chittick, Thomas M Brundage, Andrew Bae, Marion E Morrison, Vinod K Prasad. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2017 Mar; 23(3):512-521. doi:
10.1016/j.bbmt.2016.12.621. [PMID: 28063938] - Timothy K Tippin, Marion E Morrison, Thomas M Brundage, Hervé Momméja-Marin. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies.
Therapeutic drug monitoring.
2016 12; 38(6):777-786. doi:
10.1097/ftd.0000000000000353. [PMID: 27851688] - Emmanuel Faure, Tatiana Galperine, Olivier Cannesson, Sophie Alain, Viviane Gnemmi, Celine Goeminne, Annie Dewilde, Johana Béné, Mohamed Lasri, Célia Lessore de Sainte Foy, Arnaud Lionet. Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Medicine.
2016 Nov; 95(44):e5226. doi:
10.1097/md.0000000000005226. [PMID: 27858871] - Alissa J Wright, John S Gill. Strategies to prevent BK virus infection in kidney transplant recipients.
Current opinion in infectious diseases.
2016 08; 29(4):353-8. doi:
10.1097/qco.0000000000000278. [PMID: 27257795] - Michael G Ison, Randall T Hayden. Adenovirus.
Microbiology spectrum.
2016 08; 4(4):. doi:
10.1128/microbiolspec.dmih2-0020-2015. [PMID: 27726766] - Laura K McMullan, Mike Flint, Julie Dyall, César Albariño, Gene G Olinger, Scott Foster, Phiroze Sethna, Lisa E Hensley, Stuart T Nichol, E Randall Lanier, Christina F Spiropoulou. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.
Antiviral research.
2016 Jan; 125(?):71-8. doi:
10.1016/j.antiviral.2015.10.010. [PMID: 26526586] - Diana F Florescu, Andre C Kalil, Angela L Hewlett, Amy J Schuh, Ute Stroher, Timothy M Uyeki, Philip W Smith. Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2015 Sep; 61(6):969-73. doi:
10.1093/cid/civ395. [PMID: 25991468] - Genovefa A Papanicolaou, Yeon Joo Lee, James W Young, Surya V Seshan, Adam M Boruchov, Gregory Chittick, Herve Momméja-Marin, Ilya G Glezerman. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2015 May; 65(5):780-4. doi:
10.1053/j.ajkd.2014.11.020. [PMID: 25600489] - Feiyan Ma, Kaihui Nan, SuNa Lee, James R Beadle, Huiyuan Hou, William R Freeman, Karl Y Hostetler, Lingyun Cheng. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2015 Jan; 89(?):271-9. doi:
10.1016/j.ejpb.2014.12.010. [PMID: 25513956] - William S M Wold, Karoly Toth. New drug on the horizon for treating adenovirus.
Expert opinion on pharmacotherapy.
2015; 16(14):2095-9. doi:
10.1517/14656566.2015.1083975. [PMID: 26330121] - Garth D Tylden, Hans H Hirsch, Christine Hanssen Rinaldo. Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells.
Antimicrobial agents and chemotherapy.
2015; 59(6):3306-16. doi:
10.1128/aac.00238-15. [PMID: 25801568] - Ann E Tollefson, Jacqueline F Spencer, Baoling Ying, R Mark L Buller, William S M Wold, Karoly Toth. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
Antiviral research.
2014 Dec; 112(?):38-46. doi:
10.1016/j.antiviral.2014.10.005. [PMID: 25453340] - Lewis Reisman, Sabeen Habib, Gloria B McClure, Lisa S Latiolais, John A Vanchiere. Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child.
Pediatric transplantation.
2014 Nov; 18(7):E227-31. doi:
10.1111/petr.12340. [PMID: 25174393] - Diana F Florescu, Megan A Keck. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.
Expert review of anti-infective therapy.
2014 Oct; 12(10):1171-8. doi:
10.1586/14787210.2014.948847. [PMID: 25120093] - Victoria A Olson, Scott K Smith, Scott Foster, Yu Li, E Randall Lanier, Irina Gates, Lawrence C Trost, Inger K Damon. In vitro efficacy of brincidofovir against variola virus.
Antimicrobial agents and chemotherapy.
2014 Sep; 58(9):5570-1. doi:
10.1128/aac.02814-14. [PMID: 24957837] - Susanne Matthes-Martin, Heidrun Boztug, Thomas Lion. Diagnosis and treatment of adenovirus infection in immunocompromised patients.
Expert review of anti-infective therapy.
2013 Oct; 11(10):1017-28. doi:
10.1586/14787210.2013.836964. [PMID: 24073835] - Francisco M Marty, Drew J Winston, Scott D Rowley, Estil Vance, Genovefa A Papanicolaou, Kathleen M Mullane, Thomas M Brundage, Alice T Robertson, Susan Godkin, Hervé Momméja-Marin, Michael Boeckh. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
The New England journal of medicine.
2013 Sep; 369(13):1227-36. doi:
10.1056/nejmoa1303688. [PMID: 24066743] - Scott H James, Nathan B Price, Caroll B Hartline, E Randall Lanier, Mark N Prichard. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Antimicrobial agents and chemotherapy.
2013 Jul; 57(7):3321-5. doi:
10.1128/aac.00062-13. [PMID: 23650158] - Diana F Florescu, Steven A Pergam, Michael N Neely, Fang Qiu, Christine Johnston, SingSing Way, Jane Sande, Deborah A Lewinsohn, Judith A Guzman-Cottrill, Michael L Graham, Genovefa Papanicolaou, Joanne Kurtzberg, Joseph Rigdon, Wendy Painter, Herve Mommeja-Marin, Randall Lanier, Maggie Anderson, Charles van der Horst. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2012 May; 18(5):731-8. doi:
10.1016/j.bbmt.2011.09.007. [PMID: 21963623] - Wendy Painter, Alice Robertson, Lawrence C Trost, Susan Godkin, Bernhard Lampert, George Painter. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Antimicrobial agents and chemotherapy.
2012 May; 56(5):2726-34. doi:
10.1128/aac.05983-11. [PMID: 22391537] - Scott Parker, Nanhai G Chen, Scott Foster, Hollyce Hartzler, Ed Hembrador, Dennis Hruby, Robert Jordan, Randall Lanier, George Painter, Wesley Painter, John E Sagartz, Jill Schriewer, R Mark Buller. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Antiviral research.
2012 Apr; 94(1):44-53. doi:
10.1016/j.antiviral.2012.02.005. [PMID: 22381921] - Jeffrey I Cohen, Wilmer Davila, Mir A Ali, Siu-Ping Turk, Edward W Cowen, Alexandra F Freeman, Kening Wang. Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001.
The Journal of infectious diseases.
2012 Mar; 205(5):794-7. doi:
10.1093/infdis/jir853. [PMID: 22262788] - Mark N Prichard, Earl R Kern, Caroll B Hartline, E Randall Lanier, Debra C Quenelle. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.
Antimicrobial agents and chemotherapy.
2011 Oct; 55(10):4728-34. doi:
10.1128/aac.00545-11. [PMID: 21788472] - Jacqueline Ruiz, James R Beadle, R Mark Buller, Jill Schreiwer, Mark N Prichard, Kathy A Keith, Kenneth C Lewis, Karl Y Hostetler. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.
Bioorganic & medicinal chemistry.
2011 May; 19(9):2950-8. doi:
10.1016/j.bmc.2011.03.034. [PMID: 21493074] - Rainer Gosert, Christine Hanssen Rinaldo, Marion Wernli, Eugene O Major, Hans H Hirsch. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes.
Antimicrobial agents and chemotherapy.
2011 May; 55(5):2129-36. doi:
10.1128/aac.00046-11. [PMID: 21402853] - Debra C Quenelle, Bernhardt Lampert, Deborah J Collins, Terri L Rice, George R Painter, Earl R Kern. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.
The Journal of infectious diseases.
2010 Nov; 202(10):1492-9. doi:
10.1086/656717. [PMID: 20923374] - Zhi-Gang Jiang, Jeffrey Cohen, Leslie J Marshall, Eugene O Major. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.
Antimicrobial agents and chemotherapy.
2010 Nov; 54(11):4723-32. doi:
10.1128/aac.00837-10. [PMID: 20823288] - Christine Hanssen Rinaldo, Rainer Gosert, Eva Bernhoff, Solrun Finstad, Hans H Hirsch. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells.
Antimicrobial agents and chemotherapy.
2010 Nov; 54(11):4714-22. doi:
10.1128/aac.00974-10. [PMID: 20713664] - Scott Parker, Erin Touchette, Christina Oberle, Merrick Almond, Alice Robertson, Lawrence C Trost, Bernhard Lampert, George Painter, R Mark Buller. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Antiviral research.
2008 Jan; 77(1):39-49. doi:
10.1016/j.antiviral.2007.08.003. [PMID: 17904231] - Debra C Quenelle, Deborah J Collins, Bridgett P Herrod, Kathy A Keith, Julissa Trahan, James R Beadle, Karl Y Hostetler, Earl R Kern. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
Antimicrobial agents and chemotherapy.
2007 Nov; 51(11):3940-7. doi:
10.1128/aac.00184-07. [PMID: 17846137] - James R Beadle, William B Wan, Stephanie L Ciesla, Kathy A Keith, Caroll Hartline, Earl R Kern, Karl Y Hostetler. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses.
Journal of medicinal chemistry.
2006 Mar; 49(6):2010-5. doi:
10.1021/jm050473m. [PMID: 16539388] - Deborah J Bidanset, James R Beadle, W Brad Wan, Karl Y Hostetler, Earl R Kern. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.
The Journal of infectious diseases.
2004 Aug; 190(3):499-503. doi:
10.1086/421912. [PMID: 15243923]